Eagle Pharmaceuticals Inc., Esperion Therapeutics Inc., and Horizon Pharma plc have more than doubled investors' money this year.
In the multibillion-dollar market for hepatitis C, this company stands above the crowd.
Despite the threat of patent losses, our analysts believe these Big Pharma stocks would be smart investments over the next 20 years.
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
AbbVie has been an amazing growth story since its inception in 2013. However, this trend might be about to come to abrupt end. Here's why.
These three healthcare stocks could offer the best blend of sales and dividend growth in the sector.
Isis Pharmaceuticals has had an enormous run of late. Is this drugmaker still a buy?
Pfizer may be about to break up. Here's what investors need to know.
AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.
Three stock market nobles make our update for this week.